Cytokines in Shock: 1992

  • B. Beutler
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 16)


We have recently learned many lessons regarding the role of hematopoieti-cally derived cells, and the marcophage in particular, in the etiology of gram-negative septic shock. Perhaps the most important lesson, and the lesson which still invites the most avid experimentation, was that taught by the C3H/HeJ mouse. These animals carry a genetic defect, localized to the 4th chromosome [1], which deprives them of the ability to respond to lipopoly-saccharide (LPS). As a result, the mice can sustain the injection of enormous quantities of LPS; the dose-lethality curve for this strain is shifted “downfield” by a factor of 100 or more [2]. Indeed, it is not clear that the animals ever succumb to the injection of highly purified LPS preparations.


Tumor Necrosis Factor Endotoxic Shock Human Tumor Necrosis Factor Tumor Necrosis Factor Gene Tumor Necrosis Factor Receptor Family 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Watson J, Kelly K, Largen M, Taylor BA (1978) The genetic mapping of a defective LPS response gene in C3H/HeJ mice. J Immunol 120:422–424PubMedGoogle Scholar
  2. 2.
    Sultzer BM (1968) Genetic control of leucocyte responses to endotoxin. Nature 219:1253–1254PubMedCrossRefGoogle Scholar
  3. 3.
    Michalek SM, Moore RN, McGhee JR, Rosenstreich DL, Mergenhagen SE (1980) The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin. J Inf Dis 141:55–63CrossRefGoogle Scholar
  4. 4.
    Morrison DC, Ryan JL (1979) Bacterial endotoxins and host immune responses. Adv Immunol 28:293–450PubMedCrossRefGoogle Scholar
  5. 5.
    Morrison DC, Ulevitch RJ (1978) The effects of bacterial endotoxins on host mediation systems. Am J Pathol 93:526–617PubMedGoogle Scholar
  6. 6.
    Kawakami M, Cerami A (1981) Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med 154:631–639PubMedCrossRefGoogle Scholar
  7. 7.
    O’Malley WE, Achinstein B, Shear MJ (1962) Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. J Natl Cane Inst 29:1169–1175Google Scholar
  8. 8.
    Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci 72:3666–3670PubMedCrossRefGoogle Scholar
  9. 9.
    Coley WB (1893) The treatment of malignant tumors by repeated inoculations of erysipelas; with a report of ten original cases. Am J Med Sci 105:487–511CrossRefGoogle Scholar
  10. 10.
    Coley WB (1894) Treatment of inoperable malignant tumors with toxins of erysipelas and the Bacillus prodigiosus. Trans Am Surg Assoc 12:183–212Google Scholar
  11. 11.
    Coley WB (1896) The therapeutic value of the mixed toxins of the streptococcus of erysipelas in the treatment of inoperable malignant tumors, with a report of 100 cases. Am J Med Sci 112:251–281CrossRefGoogle Scholar
  12. 12.
    Coley WB (1896) Further observations upon the treatment of malignant tumors with the mixed toxins of erysipelas and Bacillus prodigiosus with a report of 160 cases. Bull Johns Hopkins Hosp 65:157–162Google Scholar
  13. 13.
    Coley WB (1906) Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and Bacillus prodigiosus. Am J Med Sci 131:375–430Google Scholar
  14. 14.
    Mannel DN, Moore RN, Mergenhagen SE (1980) Marcophages as a source of tumoricidal activity ( tumor-necrotizing factor). Inf Immun 30:523–530Google Scholar
  15. 15.
    Ruff MR, Gifford GE (1981) Rabbit tumor necrosis factor: Mechanism of action. Inf Immun 31:380–385Google Scholar
  16. 16.
    Mannel DN, Meltzer MS, Mergenhagen SE (1980) Generation and characterization of a lipo-polysaccharide-induced and serum-derived cytotoxic factor for tumor cells. Inf Immun 28:204–211Google Scholar
  17. 17.
    Beutler B, Milsark IW, Cerami A (1985) Cachectin/tumor necrosis factor: Production, destri-bution, and metabolic fate in vivo. J Immunol 135:3972–3977PubMedGoogle Scholar
  18. 18.
    Michie HR, Manogue KR, Spriggs DR, et al. (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481–1486PubMedCrossRefGoogle Scholar
  19. 19.
    Haranaka K, Satomi N, Sakurai A, Haranaka R (1984) Role of first stimulating agents in the production of tumor necrosis factor. Canc Immunol Immunother 18:87–90Google Scholar
  20. 20.
    Green S, Dobrjansky A, Chiasson MA, Carswell E, Schwartz MK, Old LJ (1977) Corynebac-terium parvum as the priming in the production of tumor necrosis factor in the mouse. J Natl Cane Inst 59:1519–1522Google Scholar
  21. 21.
    Ha DK, Gardner ID, Lawton JW (1983) Characterization of marcophage function in Myco-bacterium lepraemurium-infected mice: Sensitivity of mice to endotoxin and release of mediators and lysosomal enzymes after the endotoxin treatment. Parasite Immunol 5:513–526PubMedCrossRefGoogle Scholar
  22. 22.
    Galanos C, Freudenberg MA, Reutter W (1979) Galactosamine-induced sensitization to the lethal effects of endotoxin. Pro Natl Acad Sci 76:5939–5943CrossRefGoogle Scholar
  23. 23.
    Lehmann V, Freudenberg MA, Galanos C (1987) Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and d-galactosamine-treated mice. J Exp Med 165:657–663PubMedCrossRefGoogle Scholar
  24. 24.
    Tracey KJ, Beutler B, Lowry SF, et al. (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470–474PubMedCrossRefGoogle Scholar
  25. 25.
    Beutler B, Milsark IW, Cerami A (1985) Passive immunization against cachectin/tumor necrosis factor (TNF) protects mice from the lethal effect of endotoxin. Science 229:869–871PubMedCrossRefGoogle Scholar
  26. 26.
    Tracey KJ, Fong Y, Hesse DG, et al. (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662–666PubMedCrossRefGoogle Scholar
  27. 27.
    Mathison JC, Wolfson E, Ulevitch RJ (1988) Participation of tumor necrosis factor in the mediation of gram-negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 81:1925–1937PubMedCrossRefGoogle Scholar
  28. 28.
    Waage A, Halstensen A, Espevik T (1987) Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1:355–357PubMedCrossRefGoogle Scholar
  29. 29.
    Gamble JR, Harlan JM, Klebanoff SJ, Lopez AF, Vadas Ma (1985) Stimulation of the adherence of neutrophils to umbilicial vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci 82:8667–8671PubMedCrossRefGoogle Scholar
  30. 30.
    Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA Jr (1985) Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol 135:2069–2073PubMedGoogle Scholar
  31. 31.
    Klebanoff SJ, Vadas MA, Harlan JM, et al. (1986) Stimulation of neutrophils by tumor necrosis factor. J Immunol 136:4220–4225PubMedGoogle Scholar
  32. 32.
    Tsujimoto M, Yokota S, Vilcek J, Weissmann G (1986) Tumor necrosis factor provokes su-peroxide anion generation from neutrophils. Biochem Biophys Res Commun 137:1094–1100PubMedCrossRefGoogle Scholar
  33. 33.
    Gamble JR, Smith WB, Vadas MA (1992) TNF modulation of endothelial and neutrophil adhesion. In: Beutler B (ed) Tumor necrosis factors: The molecules and their emerging role in medicine. Raven Press, New York, NY, pp 65–86Google Scholar
  34. 34.
    Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr (1986) Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin. 1. Proc Natl Acad Sci 83:4533–4537PubMedCrossRefGoogle Scholar
  35. 35.
    Collins T, Lapierre LA, Fiers W, Strominger JL, Pober JS (1986) Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci 83:446–460PubMedCrossRefGoogle Scholar
  36. 36.
    Libby P, Ordovas JM, Auger KR, Robbins AH, Birinyi LK, Dinarello CA (1986) Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol 124:179–185PubMedGoogle Scholar
  37. 37.
    Nawroth P, Bank I, Handley D, Cassimeris J, Chess L, Stern D (1986) Tumor necrosis fac-tor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 163:1363–1375PubMedCrossRefGoogle Scholar
  38. 38.
    Pober JS, Gimbrone MA Jr, Lapierre LA, et al. (1986) Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol 127:1893–1896Google Scholar
  39. 39.
    Pober JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA Jr (1986) Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol 136:1680–1687PubMedGoogle Scholar
  40. 40.
    Pohlman TH, Stanness KA, Beatty PG, Ochs HD, Harlan JM (1986) An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin-1, and tumor necrosis fac-tor-α increases neurtophil adherence by a CDw18-dependent mechanism. J Immunol 136:4548–4553PubMedGoogle Scholar
  41. 41.
    Fong Y, Tracey KJ, Moldawer LL, et al. (1989) Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 ß and interleukin 6 appearance during lethal bacteremia. J Exp Med 170:1627–1633PubMedCrossRefGoogle Scholar
  42. 42.
    Eisenberg SP, Evans RJ, Arend WP, et al. (1990) Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343:341–346PubMedCrossRefGoogle Scholar
  43. 43.
    Hammun CH, Wilcox CJ, Arend WP, et al. (1990) Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343:336–340CrossRefGoogle Scholar
  44. 44.
    Dinarello CA, Thompson RC (1991) Blocking IL-1: Interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 12:404–409PubMedCrossRefGoogle Scholar
  45. 45.
    Broxmeyer HE, Williams DE, Lu L, et al. (1986) The suppressive influence of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: Synergism of tumor necrosis factor and interferon-γ. J Immunol 136:4487–4495PubMedGoogle Scholar
  46. 46.
    Sone S, Lopez-Berestein G, Fidler IJ (1986) Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-γ and muramyl dipeptide derivatives. Canc Immunol Immunother 21:93–99Google Scholar
  47. 47.
    Tsujimoto M, Feinman R, Vilcek J (1986) Differential effects of type I IFN and IFN-γ on the binding of tumor necrosis factor to receptors in two human cell lines. J Immunol 137:2272–2276PubMedGoogle Scholar
  48. 48.
    Esparza I, Marmel D, Ruppel A, Falk W, Krammer PH (1987) Interferon-γ (IFN-γ) and lym-photoxin (LT) or tumor necrosis factor (TNF) synergize to activate macrophages for tumori-cidal and schistosomulicidal functions. Lymphokine Res (Abs) 6:1715Google Scholar
  49. 49.
    Tribble H, Schneider M, Bowersox O, Talmadge JE (1987) Combination immunotherapy with RH TNF and RM IFN G: Increased therapy and toxicity. Fed Proc (Abs) 46:561Google Scholar
  50. 50.
    Agah R, Malloy B, Sherrod A, Mazumder A (1988) Successful therapy of natural killer-resistant pulmonary metastases by the synergism of y-interferon with tumor necrosis factor and interleukin-2 in mice. Cancer Res 48:2245–2248PubMedGoogle Scholar
  51. 51.
    Chapekar MS, Glazer RI (1988) The synergistic cytocidal effect produced by immune interferon and tumor necrosis factor in HT-29 cells in associated with inhibition of rRNA processing and (2′, 5′) oligo (A) activation of RNase L. Biochem Biophy Res Comm 151:1180–1187CrossRefGoogle Scholar
  52. 52.
    Bonavida B, Jewett A (1989) Activation of human peripheral blood-derived monocytes by OK-432 (Strecptococcus pyogenes): Augmented cytotoxicity and secretion of TNF and synergy with rIFN-γ. Cell Immunol 123:373–383PubMedCrossRefGoogle Scholar
  53. 53.
    Barker JNWN, Sarma V, Mitra RS, Dixit VM, Nickoloff BJ (1990) Marked synergism between tumor necrosis factor-α and interferon-γ in regulation of keratinocyte-derived adhesion molecules and chemotactic factors. J Clin Invest 83:605–608CrossRefGoogle Scholar
  54. 54.
    Beresini MH, Sugarman BJ, Shepard HM, Epstein LB (1990) Synergistic induction of poly-peptides by tumor necrosis factor and interferon-γ in cells sensitive or resistant to tumor necrosis factor: Assessment by computer based analysis of two-dimensional gels using the PDQUEST system. Electrophoresis 11:232–241PubMedCrossRefGoogle Scholar
  55. 55.
    Kumaratilake LM, Ferrante A, Bates EJ, Kowanko IC (1990) Augmentation of the human monocyte/macrophage chemiluminescence response during short-term exposure to interfe-— ron-γ and tumor necrosis factor-α. Clin Exp Immunol 80:257–262PubMedCrossRefGoogle Scholar
  56. 56.
    Matsuura M, Galanos C (1990) Induction of hypersensivitiy to endotoxin and tumor necrosis factor by sublethal infection with Salmonella typhimurium. Infect Immun 58:935–937PubMedGoogle Scholar
  57. 57.
    Pfitzenmaier K, Himmler A, Schütze S, Scheurich P, Kronke M (1992) TNF receptors and TNF signal transduction. In: Beutler B (ed) Tumor necrosis factors: The molecules and their emerging role in medicine. Raven Press, New York, pp 439–472Google Scholar
  58. 58.
    Pennica D, Nedwin GE, Hayflick JS, et al. (1984) Human tumor necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature 312:724–729PubMedCrossRefGoogle Scholar
  59. 59.
    Marsters SA, Frutkin AD, Simpson NJ, Fendly BM, Ashkenazi A (1992) Identification of cy-steine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding. J Biol Chem 267:5747–5750PubMedGoogle Scholar
  60. 60.
    Eck MJ, Sprang SR (1989) The structure of tumor necrosis factor-α at 2.6 A resolution: Implications for receptor binding. J Biol Chem 264:17595–17605PubMedGoogle Scholar
  61. 61.
    Engelmann H, Holtmann H, Brakebusch C, et al. (1990) Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 265:14497–14504PubMedGoogle Scholar
  62. 62.
    Brett J, Gerlach H, Nawroth P, Steinberg S, Godman S, Stern D (1989) Tumor necrosis fac-tor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med 169:1977–1991PubMedCrossRefGoogle Scholar
  63. 63.
    Roederer M, Staal FJT, Raju PA, Ela SW, Herzenberg LA (1990) Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Natl Acad Sci USA 87:4884–4888PubMedCrossRefGoogle Scholar
  64. 64.
    Wong GHW, Elwell JH, Oberley LW, Goeddel DV (1989) Manganous Superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 58:923–931PubMedCrossRefGoogle Scholar
  65. 65.
    Baglioni C (1992) Mechanisms of cytotoxicity, cytolysis, and growth stimulation by TNF. In: Beutler (ed) Tumor necrosis factors: The molecules and their emerging role in medicine. Raven Press, New York, pp 425–472Google Scholar
  66. 66.
    Yonehara S, Ishii A, Yonehara M (1989) A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down-regulated with the receptor of tumor necrosis factor. J Exp Med 169:1747–1756PubMedCrossRefGoogle Scholar
  67. 67.
    Itoh N, Yonehara S, Ishii A, et al. (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233–243PubMedCrossRefGoogle Scholar
  68. 68.
    Watanabe-Fukunaga R, Brannan CI, Itoh N, et al. (1992) The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 148:1274–1279PubMedGoogle Scholar
  69. 69.
    Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S (1992) Lympho-proliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314–317PubMedCrossRefGoogle Scholar
  70. 70.
    Sprang SR, Eck MJ (1992) The 3-D Structure of TNF: In Beutler B (ed) Tumor necrosis factors: The molecules and their emerging role in medicine. Raven Press, New York, pp 11–32Google Scholar
  71. 71.
    Van Ostade X, Vandenabeele P, Everaerdt B, et al. (1992) Human TNF mutants with reduced binding to the TNF-R75. Eur Cyto Net (Abs.) 3:137–137Google Scholar
  72. 72.
    Dente L, Ciliberto G, Cortese R (1985) Structure of the human α-1-acid glycoprotein gene: Sequence homology with other human acute phase protein genes. Nucleic Acids Res 13:3941–3952PubMedCrossRefGoogle Scholar
  73. 73.
    Sauder DN (1984) Epidermal cytokines: Properties of epidermal cell thymocyte-activating factor (ETAF). Lymphokine Res 3:145–151PubMedGoogle Scholar
  74. 74.
    Küpper TS, Ballard DW, Chua AO, et al. (1986) Human keratinocytes contain mRNA indistinguishable from monocyte interleukin 1α and ß mRNA. J Exp Med 164:2095–2100PubMedCrossRefGoogle Scholar
  75. 75.
    Giulian D, Baker TJ, Shih LN, Lachman LB (1986) Interleukin-1 of the central nervous system is produced by ameboid microglia. J Exp Med 164:594–604PubMedCrossRefGoogle Scholar
  76. 76.
    Chung IY, Benveniste EN (1990) Tumor necrosis factor-α production by astrocytes: Induction by lipopolyaccharide, IFN-γ, and IL-lß. J Immunol 144:2999–3007PubMedGoogle Scholar
  77. 77.
    Poubelle PE, Grassi J, Pradelles P, Marceau F (1990) Pharmacological modulation of interleukin 1 production by cultured endothelial cells from human umbilical veins. Immunophar-macology 19:121–130Google Scholar
  78. 78.
    Spriggs DR, Imamura K, Rodriguez C, Sariban E, Kufe DW (1988) Tumor necrosis factor expression in human epithelial tumor cell lines. J Clin Invest 81:455–460PubMedCrossRefGoogle Scholar
  79. 79.
    Hsu P-L, Hsu S-M (1989) Production of tumor necrosis factor-α and lymphotoxin by cells of Hodgkin’s neoplastic cell lines HDLM-1 and KM-H2. Am J Pathol 135:735–745PubMedGoogle Scholar
  80. 80.
    Gowen M, Chapman K, Littlewood A, Hughes D, Evans D, Russell G (1990) Production of tumor necrosis factor by human osteoblasts is modulated by other cytokines, but not by osteotropic hormones. Endocrinology 126:1250–1255PubMedCrossRefGoogle Scholar
  81. 81.
    Ohno I, Tanno Y, Yamauchi K, Takishima T (1990) Gene expression and production of tumor necrosis factor by a rat basophilic leukaemia cell line (RBL-2H3) with IgE receptor triggering. Immunology 70:88–93PubMedGoogle Scholar
  82. 82.
    Ohno I, Tanno Y, Yamauchi K, Takishima T (1990) Production of tumor necrosis factor by mastocytoma P815 cells. Immunology 69:312–315PubMedGoogle Scholar
  83. 83.
    Zolti M, Meirom R, Shemesh M, Wollach D, Mashiach S, Shore L, Rafael ZB (1990) Granu-losa cells are a source and target organ for tumor necrosis factor-α. FEBS Lett 261:253–255PubMedCrossRefGoogle Scholar
  84. 84.
    Jaattela M, Kuusela P, Saksela E (1988) Demonstration of tumor necrosis factor in human amniotic fluids and supernatants of placental and decidual tissues. Lab Invest 58:48–52PubMedGoogle Scholar
  85. 85.
    Tovey MG, Content J, Gresser I, et al. (1988) Genes for IFN-ß-2 (IL-6), tumor necrosis factor, and IL-1 are expressed at high levels in the organs of normal individuals. J Immunol 141:3106–3110PubMedGoogle Scholar
  86. 86.
    Ulich TR, Guo K, Castillo JD (1989) Endotoxin-induced cytokine gene expression in vivo. I. Expression of tumor necrosis factor mRNA in visceral organs under physiologic conditions and during endotoxemia. Am J Pathol 134:11–14PubMedGoogle Scholar
  87. 87.
    Kossodo S, Giroir B, Brown T, Pointaire P, Grau G, Beutler B (1991) Constitutive expression of cachectin/TNF in the thymus: Fulfillment of an essential developmental function. Clinical Res (Abs) 39:250AGoogle Scholar
  88. 88.
    Giroir BP, Brown T, Beutler B (1992) Constitutive synthesis of tumor necrosis factor in the thymus. Proc Natl Acad Sci (In Press)Google Scholar
  89. 89.
    Giroir BP, Johnson JH, Brown T, Allen GL, Beutler B (1992) The tissue distribution of TNF biosynthesis during endotoxemia. J Clin Invest (In Press)Google Scholar
  90. 90.
    Shaw G, Kamen R (1986) A conserved AU sequence from the 3’ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46:659–667PubMedCrossRefGoogle Scholar
  91. 91.
    Kruys V, Marinx O, Shaw G, Deschamps J, Huez G (1989) Translational blockade imposed by cytokine-derived UA-rich sequences. Science 245:852–855PubMedCrossRefGoogle Scholar
  92. 92.
    Han J, Brown T, Beutler B (1990) Endotoxin-responsive sequences control cachectin/TNF biosynthesis at the translational level. J Exp Med 171:465–475PubMedCrossRefGoogle Scholar
  93. 93.
    Han J, Beutler B (1990) The essential role of the UA-rich sequence in endotoxin-induced cachectin/TNF synthesis. Eur Cyto Net 1:71–75Google Scholar
  94. 94.
    Beutler B, Brown T (1991) A CAT reporter construct allows ultrasensitive estimation of TNF synthesis, and suggests that the TNF gene has been silenced in non-macrophage cell lines. J Clin Invest 87:1336–1344PubMedCrossRefGoogle Scholar
  95. 95.
    Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A (1986) Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance. Science 232:977–980PubMedCrossRefGoogle Scholar
  96. 96.
    Han J, Thompson P, Beutler B (1990) Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/TNF synthesis at separate points in the signaling pathway. J Exp Med 172:391–394PubMedCrossRefGoogle Scholar
  97. 97.
    Giroir BP, Beutler B (1992) Effect of amrinone on tumor necrosis factor production in en-dotoxic shock. Circulatory Shock 36:200–207PubMedGoogle Scholar
  98. 98.
    Havell EA (1989) Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 143:2894–2899PubMedGoogle Scholar
  99. 99.
    Grau GE, Fajardo LF, Piguet PF, Allet B, Lambert PH, Vassalli P (1987) Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 237:1210–1212PubMedCrossRefGoogle Scholar
  100. 100.
    Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P (1989) The inducing role of tumor necrosis factor in the development of bacterial granulomas during BCG infection. Cell 56:731–740PubMedCrossRefGoogle Scholar
  101. 101.
    Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550–552PubMedCrossRefGoogle Scholar
  102. 102.
    Peppel K, Crawford D, Beutler B (1991) A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 174:1483–1489PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • B. Beutler

There are no affiliations available

Personalised recommendations